CagriSema vs Tirzepatide (REDEFINE 4): strong weight loss, but an important endpoint miss Novo Nordisk has announced headline results from the open-label phase 3 REDEFINE 4 trial comparing CagriSema (cagrilintide + semaglutide) vs tirzepatide 15 mg in obesity
Most newly developed pharmacon candidates to treat neurological diseases are not able to cross the BBB and reach their target(s) within the brain [3]
Lilly awaits US approval for its weight-loss pill, possibly by March
This section is mandatory reading before working with MT1 in any laboratory setting
Common side effects are nausea, vomiting, diarrhea, and constipationall gastrointestinal
Recalls & Warnings February 13, 2013 FDA Warns Maker of Weight Loss and Whey Protein Supplements For Manufacturing Violations and Misbranding January 25, 2013, the FDA issued a warning letter to dietary supplement manufacturer SciLabs Nutraceuticals, following a facility inspection which found the company's dietary supplements and supplement ingredients, including N-Large 2, Flo-Gard AB, Nitrogen Glutamine capsules, Nutritech nutritional
